Skip to main content

Jonathan Wise is a member of Greenberg Traurig’s Intellectual Property Litigation team. Jon has a wide range of experience advising clients and litigating intellectual property matters in a variety of industries, with deep experience handling pharmaceutical patent cases under the Hatch-Waxman Act. He regularly prepares opinions and provides client counseling on patentability, infringement, and validity issues.

Prior to joining GT, Jon was Associate General Counsel of IP Litigation at a global pharmaceutical company. As in-house counsel, he coordinated and executed patent litigation strategy on dozens of U.S. pharmaceutical patent cases filed under the Hatch-Waxman Act; managed a team of lawyers responsible for generic pharmaceutical patent cases; performed freedom-to-operate and patentability analyses; regularly advised senior management on litigation risks and results; conducted internal training on patent litigation, patentability of inventions, and the U.S. discovery process at company sites around the world; and negotiated many case settlements.

Before serving as in-house counsel, Jon litigated patent cases and counseled clients at an intellectual property boutique in New York City. There, he worked on a wide variety of matters representing brand and generic pharmaceutical companies, as well as companies focused on DVDs, computerized controllers, and medical devices.

Jon has also represented veterans in pro bono cases before the U.S. Court of Appeals for Veterans Claims to help them obtain their service-connected disability benefits.

Concentrations

  • Patent, trademark, and trade secret litigation
  • ANDA Hatch-Waxman litigation
  • Medical device litigation
  • General IP counseling, due diligence, opinions, and inter partes review proceedings

Capabilities

Experience

  • Neurocrine Biosciences Inc. v. Teva Pharmaceuticals USA, Inc.: Representing Teva in its Paragraph IV challenge to Neurocrine’s patents in the District of Delaware relating to a generic version of Ingrezza®.
  • Jonathan Berall, M.D., M.P.H. v. Teleflex Medical Incorporated: Representing Teleflex in a medical device case in the Southern District of New York.
  • Smile Brands, Inc. v. Castle Dental, LLC.: Represented Smile Brands in a trademark infringement case in the Eastern District of Pennsylvania.
  • CMP Development LLC v. Amneal Pharmaceuticals LLC: Represented Amneal in its Paragraph IV challenge to CMP’s patents in the District of Delaware relating to a generic version of Carospir®.
  • Almirall, LLC v. Amneal Pharmaceuticals LLC: Representing Amneal in its Paragraph IV challenge to Almirall’s patents in the District of Delaware relating to a generic version of Aczone® Gel, 7.5%.
  • Keryx Biopharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc.: Represented Teva in its Paragraph IV challenge to Keryx’s patents in the District of Delaware relating to a generic version of Auryxia®.
  • Collegium Pharmaceutical, Inc. v. Teva Pharmaceuticals USA, Inc.: Represented Teva in its Paragraph IV challenge to Collegium’s patents in the District of Delaware relating to a generic version of Xtampza®.
  • Egalet US, Inc. v. Teva Pharmaceuticals USA, Inc.: Represented Teva in its Paragraph IV challenge to Egalet’s patents in the District of Delaware relating to a generic version of Arymo®Teva obtained a dismissal of the case with prejudice.
  • Vifor Fresenius Medical Care Renal Pharma Ltd. v. Teva Pharmaceuticals USA, Inc.: Representing Teva in its Paragraph IV challenge to Vifor’s patents in the District of Delaware relating to a generic version of Velphoro®.
  • Worked with teams to obtain favorable trial and appellate court decisions in Hatch-Waxman cases involving drug products Actonel®, Aloxi®, Ampyra®, Atelvia®, Celebrex®, Lovaza®, Namenda XR®, and OxyContin®
  • Negotiated settlements in Hatch-Waxman cases involving drug products Aubagio®, Bunavail®, Celebrex®, Cubicin®, Fazaclo®, Folotyn®, Lunesta®, Namenda XR®, Nexium 24hr OTC, Oxycontin®, Rozerem®, Travatan Z®, Viagra®, Vytorin®, Zetia®, Zyvox®
  • Served as a member of the team representing Teva in the 2017 LMG Life Sciences Patent Impact Case of the Year (GlaxoSmithKline LLC, et al. v. Teva Pharmaceuticals USA, Inc.).°
  • Litigated patent cases for technology companies specializing in DVDs and controllers used in cooking ovens.°
  • Represented disabled veterans in pro-bono cases before the U.S. Court of Appeals for Veterans Claims. (Coderre v. Peak, No. 06-2266; Schuh v. Gibson, No. 12-3100).°

°The above representations were handled by Mr. Wise prior to his joining Greenberg Traurig, LLP.

  • Associate General Counsel – IP Litigation, Teva Pharmaceuticals, 2010-2018
  • Legal Intern, Hon. Arthur J. Gajarsa, U.S. Court of Appeals for the Federal Circuit

Recognition & Leadership

  • Listed, Managing IP Magazine's World IP Handbook and Survey, “Notable Practitioner,” 2021
  • Listed, Managing IP Magazine's World IP Handbook and Survey, "Rising Star - United States," 2019

Credentials

Education
  • J.D., University of New Hampshire School of Law, 2005
    • Chief Articles Editor, Pierce Law Review
  • M.B.A., Temple University Fox School of Business
  • B.S., Chemical Engineering, Pennsylvania State University, 2002
Admissions
  • Pennsylvania
  • New York
  • U.S. Patent and Trademark Office